Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Altamira Therapeutics (Nasdaq:CYTO) has announced an extension of its exclusive distribution agreement for Bentrio with Pharma Nordic AS to include Sweden and Denmark, in addition to Norway. This follows the successful launch of Bentrio in Norway earlier in 2024. Pharma Nordic plans to introduce the nasal spray for prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.
The CEO of Altamira Medica, Thomas Meyer, expressed satisfaction with Pharma Nordic's market launch activities in Norway. Bent Andreassen, CEO of Pharma Nordic, noted favorable responses from the medical community and patients, highlighting Bentrio's drug-free and preservative-free formulation as well as its efficacy and tolerability data.
Altamira Therapeutics (Nasdaq:CYTO) ha annunciato un'estensione del suo accordo di distribuzione esclusivo per Bentrio con Pharma Nordic AS per includere la Svezia e la Danimarca, oltre alla Norvegia. Questo segue il lancio di successo di Bentrio in Norvegia all'inizio del 2024. Pharma Nordic prevede di introdurre lo spray nasale per la prevenzione e il trattamento della rinite allergica in questi due ulteriori paesi scandinavi il prossimo anno.
Il CEO di Altamira Medica, Thomas Meyer, ha espresso soddisfazione per le attività di lancio di mercato di Pharma Nordic in Norvegia. Bent Andreassen, CEO di Pharma Nordic, ha notato risposte favorevoli dalla comunità medica e dai pazienti, evidenziando la formulazione priva di farmaci e conservanti di Bentrio, così come i dati sulla sua efficacia e tollerabilità.
Altamira Therapeutics (Nasdaq:CYTO) ha anunciado una extensión de su acuerdo de distribución exclusiva para Bentrio con Pharma Nordic AS para incluir Suecia y Dinamarca, además de Noruega. Esto sigue al exitoso lanzamiento de Bentrio en Noruega a principios de 2024. Pharma Nordic planea introducir el spray nasal para la prevención y tratamiento de la rinitis alérgica en estos dos países escandinavos adicionales el próximo año.
El CEO de Altamira Medica, Thomas Meyer, expresó su satisfacción con las actividades de lanzamiento de mercado de Pharma Nordic en Noruega. Bent Andreassen, CEO de Pharma Nordic, destacó las respuestas favorables de la comunidad médica y los pacientes, subrayando la formulación libre de medicamentos y conservantes de Bentrio, así como sus datos de eficacia y tolerabilidad.
Altamira Therapeutics (Nasdaq:CYTO)는 Bentrio의 독점 유통 계약을 Pharma Nordic AS와 연장하여 노르웨이에 추가하여 스웨덴과 덴마크를 포함하기로 했습니다. 이는 2024년 초 노르웨이에서 Bentrio의 성공적인 출시를 이어가는 것입니다. Pharma Nordic은 내년에 이 두 개의 추가 스칸디나비아 국가에서 알레르기 비염의 예방 및 치료를 위한 비강 스프레이를 도입할 계획입니다.
Altamira Medica의 CEO인 Thomas Meyer는 노르웨이에서 Pharma Nordic의 시장 출시 활동에 대한 만족감을 표명했습니다. Pharma Nordic의 CEO인 Bent Andreassen은 의료 공동체와 환자들로부터 긍정적인 반응을 받았으며, Bentrio의 약물과 방부제가 없는 제형뿐만 아니라 효과와 내약성 데이터에 대해 강조했습니다.
Altamira Therapeutics (Nasdaq:CYTO) a annoncé une extension de son accord de distribution exclusif pour Bentrio avec Pharma Nordic AS pour inclure la Suède et le Danemark, en plus de la Norvège. Cela fait suite au lancement réussi de Bentrio en Norvège au début de 2024. Pharma Nordic prévoit d'introduire le spray nasal pour la prévention et le traitement de la rhinite allergique dans ces deux nouveaux pays scandinaves l'année prochaine.
Le PDG d'Altamira Medica, Thomas Meyer, a exprimé sa satisfaction quant aux activités de lancement de marché de Pharma Nordic en Norvège. Bent Andreassen, PDG de Pharma Nordic, a noté des réponses favorables de la part de la communauté médicale et des patients, mettant en avant la formulation sans médicament et sans conservateur de Bentrio ainsi que ses données d'efficacité et de tolérance.
Altamira Therapeutics (Nasdaq:CYTO) hat eine Erweiterung seines exklusiven Vertriebsvertrags für Bentrio mit Pharma Nordic AS bekannt gegeben, um Schweden und Dänemark zusätzlich zu Norwegen einzuschließen. Dies folgt auf die erfolgreiche Einführung von Bentrio in Norwegen Anfang 2024. Pharma Nordic plant, das Nasenspray zur Prävention und Behandlung von allergischer Rhinitis im nächsten Jahr in diesen beiden zusätzlichen skandinavischen Ländern einzuführen.
Der CEO von Altamira Medica, Thomas Meyer, äußerte Zufriedenheit mit den Markteinführungsaktivitäten von Pharma Nordic in Norwegen. Bent Andreassen, CEO von Pharma Nordic, bemerkte positive Rückmeldungen von der Ärzteschaft und den Patienten und hob die medikamentenfreie und konservierungsmittelfreie Formulierung von Bentrio sowie dessen Wirksamkeits- und Verträglichkeitsdaten hervor.
- Successful launch of Bentrio in Norway in 2024
- Expansion of distribution agreement to include Sweden and Denmark
- Favorable responses from medical community and patients in Norway
- Unique positioning of Bentrio with drug-free and preservative-free formulation
- None.
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) --
- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024
- Exclusive distribution agreement extended to also include Sweden and Denmark
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.
“We have been very pleased and impressed by Pharma Nordic’s market launch activities and success in Norway,” commented Thomas Meyer, Altamira Medica’s Chairman and CEO. “It is therefore of mutual interest to expand in a next step the geographical scope of our collaboration to include Sweden and Denmark. We look forward to bringing Bentrio to patients in these two other countries and to continuing to build the product together with Pharma Nordic into one of the leading brands for allergic rhinitis management in Scandinavia.”
“We received very favorable responses to Bentrio from members of the medical community and allergic rhinitis sufferers in Norway, showing a clear need for effective and safe treatment alternatives” stated Bent Andreassen, CEO of Pharma Nordic. “With its drug-free and preservative-free formulation, as well as strong data on efficacy and tolerability, Bentrio is uniquely positioned to address patients’ unmet needs. We are very excited to continue the roll-out in Norway and to take Bentrio into the Swedish and Danish markets, which share many things in common, notably a passion for innovative health care products.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one (“NASAR” study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 times per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
About Pharma Nordic
Pharma Nordic AS, Aalsund, Norway holds licenses in the Nordic countries on over-the-counter (OTC) medicines and medical-technical equipment that are already on the world market or are about to be launched on markets outside the Nordic countries. For more information, visit: https://www.pharmanordic.no/
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What is the latest news about Altamira Therapeutics' Bentrio distribution?
When was Bentrio launched in Norway by Pharma Nordic?
What is Bentrio used for according to the Altamira Therapeutics press release?
When does Pharma Nordic plan to introduce Bentrio in Sweden and Denmark?
